Table 1.

Approved drugs that target interleukin-6 signaling.

Compound	Target	Medical conditions
Baricitinib	JAK-1, JAK-2	Rheumatoid arthritis, atopic dermatitis
Filgotinib	JAK-1	Rheumatoid arthritis
Ruxolitinib	JAK-1, JAK-2	Myelofibrosis, polycythaemia vera
Sarilumab	IL-6R	Rheumatoid arthritis
Siltuximab	IL-6	Castleman disease
Tocilizumab	IL-6R	Rheumatoid arthritis, juvenile idiopathic arthritis, Castleman disease, giant cell arteritis, cytokine release syndrome
Tofacitinib	JAK-1, JAK-2, JAK-3	Rheumatoid arthritis, Psoriatic arthritis, ulcerative colitis
Upadacitinib	JAK-1	Rheumatoid arthritis